Stocks Health care SLS
NASDAQ · Health careSELLAS Life Sciences Group, Inc. (SLS)
It posted a net loss of $32.5M. At June 30, 2026 it held $138.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about SELLAS Life Sciences Group, Inc.
- Net worth
- SELLAS Life Sciences Group, Inc. has a market value (market cap) of $1.7B at the latest share price, and shareholders' equity of $137.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $0 (-100.0% year on year), with a net loss of $37.3M.
- Cash flow
- In fiscal 2025 operations used $28.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- SELLAS Life Sciences Group, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What SELLAS Life Sciences Group, Inc. does
SELLAS Life Sciences Group, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SLS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26.9M | -$0.25 | n/a |
| 2024 | n/a | -$30.9M | -$0.50 | n/a |
| 2023 | $0 | -$37.3M | -$1.34 | n/a |
| 2022 | $1M | -$41.3M | -$2.13 | n/a |
| 2021 | $7.6M | -$20.7M | -$1.34 | n/a |
| 2020 | $1.9M | -$16.8M | -$2.11 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2019 | n/a | $0 | n/a |
| 2018 | n/a | $487K | n/a |
| 2017 | n/a | $0 | n/a |
Latest SEC filings
What SELLAS Life Sciences Group, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026
- June 25, 2026
- June 18, 2026
- June 16, 2026
- June 2, 2026Other event 8-K
Insider trades
What the people running SELLAS Life Sciences Group, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 16, 2026 | Stergiou Angelos M.President and CEO, Director | Received as pay | 1,065,000 | - |
| January 7, 2026 | Wasman JaneDirector | Received as pay | 50,000 | - |
| January 7, 2026 | Kalin Katherine BachDirector | Received as pay | 50,000 | - |
| January 7, 2026 | Burns John ThomasCFO | Received as pay | 300,000 | - |
| January 7, 2026 | Cicic DraganSVP, Chief Development Officer | Received as pay | 300,000 | - |
| January 7, 2026 | Scheinberg David ADirector | Received as pay | 50,000 | - |
| January 7, 2026 | Van Nostrand Robert LDirector | Received as pay | 50,000 | - |
| January 7, 2026 | Varian JohnDirector | Received as pay | 50,000 | - |
Who owns SLS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 7.9% | October 27, 2026 |
| Vanguard Capital Management13G, passive | 5.19% | July 31, 2026 |
Largest institutional holders
Insiders
8 insiders reported holding 3,347,497 shares in total, about $28.7M at the last price.
| Holder | Shares |
|---|---|
| Stergiou Angelos M.President and CEO, Director | 1,759,183 |
| Cicic DraganSVP, Chief Development Officer | 557,805 |
| Burns John ThomasCFO | 554,327 |
| Kalin Katherine BachDirector | 154,400 |
| Wasman JaneDirector | 92,900 |
| Van Nostrand Robert LDirector | 82,900 |
| Scheinberg David ADirector | 73,082 |
| Varian JohnDirector | 72,900 |
Questions about SLS
What does SELLAS Life Sciences Group, Inc. do?
SELLAS Life Sciences Group, Inc. is a company in the Health care sector, listed on NASDAQ as SLS. Its shares trade on NASDAQ under the ticker SLS.
What is SELLAS Life Sciences Group, Inc.'s net worth?
SELLAS Life Sciences Group, Inc. has a market value (market cap) of $1.7B at the latest share price, and shareholders' equity of $137.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is SELLAS Life Sciences Group, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $32.5M.
When did SELLAS Life Sciences Group, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 27, 2026.
When is SELLAS Life Sciences Group, Inc.'s next earnings report?
SELLAS Life Sciences Group, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SLS with
Follow SLS
Get an email when SELLAS Life Sciences Group, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values SELLAS Life Sciences Group, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.